^
Association details:
| Biomarker: | CD19 expression + Chr t(8;21) |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug Class: | CD19-targeted CAR-T immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
Published date:
05/11/2023
Excerpt:
We presented 6 pts with R/PR t (8; 21) AML with aberrant CD19 expression after multiple lines of therapies (4 post allo-SCT), treated by point of care CD19 CAR T-cells with 4 pts achieving CR.
Trial ID:
